Nurix expands licensing deal with Sanofi

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases. Nurix closed up 8.7% at $11.38 following the news.

The undisclosed target is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program.

Under the new deal, French pharma major Sanofi has the right to license drug candidates resulting from the work, and Nurix has the option to co-develop and co-promote up to two future products in the USA after studies to assess dosing, efficacy, and safety that provide clinical proof of concept. For those programs for which Nurix exercises its option to co-develop and co-promote, the parties will split US profits and losses evenly and Nurix will be eligible to receive royalties on ex-US sales on all optioned products. For programs that Nurix does not exercise its option, Nurix will receive milestones and royalties based on global development and sales.